• Inborn errors of metabolism

Vimizim Generic Name & Formulations

General Description

Elosulfase alfa 1mg/mL; soln for IV infusion; preservative-free.

Pharmacological Class

Hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme.

How Supplied

Single-use vial (5mL)—1

Vimizim Indications


Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Vimizim Dosage and Administration

Adults and Children

<5yrs: not established. Give by IV infusion over 3.5–4.5 hours based on infusion volume. ≥5yrs: 2mg/kg once weekly. Pre-treat with antihistamines with or without antipyretics 30–60 mins prior to infusion.

Vimizim Contraindications

Not Applicable

Vimizim Boxed Warnings

Boxed Warning

Risk of anaphylaxis.

Vimizim Warnings/Precautions


Risk of serious anaphylactic reactions; observe patients during and after administration. Have epinephrine inj available. Discontinue immediately if severe hypersensitivity reactions occur. Acute febrile or respiratory illness; evaluate clinical status prior to therapy and consider delaying infusion. Risk of sleep apnea; consider evaluating airway patency prior to initiation. Have supplemental oxygen or continuous positive airway pressure available. Monitor for signs/symptoms of spinal or cervical cord compression. Pregnancy. Nursing mothers.

Vimizim Pharmacokinetics

See Literature

Vimizim Interactions

Vimizim Adverse Reactions

Adverse Reactions

Pyrexia, vomiting, headache, nausea, abdominal pain, chills, fatigue; sleep apnea, anaphylaxis, possible antibody formation.

Vimizim Clinical Trials

See Literature

Vimizim Note


To enroll in the Morquio A Registry for monitoring effects of Vimizim contact [email protected] or call (800) 983-4587.

Vimizim Patient Counseling

See Literature